- Home
- ACOG vs ATRA Comparison
ACOG vs ATRA Comparison
Compare ACOG & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- ATRA
- Stock Information
- Founded
- ACOG 2000
- ATRA 2012
- Country
- ACOG Canada
- ATRA United States
- Employees
- ACOG N/A
- ATRA N/A
- Industry
- ACOG
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACOG
- ATRA Health Care
- Exchange
- ACOG Nasdaq
- ATRA Nasdaq
- Market Cap
- ACOG 80.3M
- ATRA 67.9M
- IPO Year
- ACOG N/A
- ATRA 2014
- Fundamental
- Price
- ACOG $9.73
- ATRA $11.95
- Analyst Decision
- ACOG Strong Buy
- ATRA Strong Buy
- Analyst Count
- ACOG 1
- ATRA 3
- Target Price
- ACOG $20.00
- ATRA $21.00
- AVG Volume (30 Days)
- ACOG 81.7K
- ATRA 60.0K
- Earning Date
- ACOG 08-14-2025
- ATRA 08-11-2025
- Dividend Yield
- ACOG N/A
- ATRA N/A
- EPS Growth
- ACOG N/A
- ATRA N/A
- EPS
- ACOG N/A
- ATRA 0.56
- Revenue
- ACOG $4,586,341.00
- ATRA $188,667,000.00
- Revenue This Year
- ACOG N/A
- ATRA N/A
- Revenue Next Year
- ACOG $149.89
- ATRA N/A
- P/E Ratio
- ACOG N/A
- ATRA $21.25
- Revenue Growth
- ACOG N/A
- ATRA 202.41
- 52 Week Low
- ACOG $3.75
- ATRA $5.01
- 52 Week High
- ACOG $11.54
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- ACOG 61.91
- ATRA 50.90
- Support Level
- ACOG $8.01
- ATRA $11.70
- Resistance Level
- ACOG $8.34
- ATRA $13.20
- Average True Range (ATR)
- ACOG 0.48
- ATRA 0.70
- MACD
- ACOG 0.21
- ATRA -0.07
- Stochastic Oscillator
- ACOG 94.62
- ATRA 35.14
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).